Annual Cash & Cash Equivalents
$131.54 M
-$41.80 M-24.11%
31 December 2023
Summary:
Achilles Therapeutics annual cash & cash equivalents is currently $131.54 million, with the most recent change of -$41.80 million (-24.11%) on 31 December 2023. During the last 3 years, it has fallen by -$134.78 million (-50.61%). ACHL annual cash & cash equivalents is now -50.61% below its all-time high of $266.32 million, reached on 31 December 2021.ACHL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$86.05 M
-$9.06 M-9.52%
01 September 2024
Summary:
Achilles Therapeutics quarterly cash and cash equivalents is currently $86.05 million, with the most recent change of -$9.06 million (-9.52%) on 01 September 2024. Over the past year, it has dropped by -$45.49 million (-34.58%). ACHL quarterly cash and cash equivalents is now -71.25% below its all-time high of $299.32 million, reached on 30 June 2021.ACHL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACHL Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -34.6% |
| 3 y3 years | -50.6% | -67.7% |
| 5 y5 years | +34.8% | - |
ACHL Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -50.6% | at low | -67.7% | at low |
| 5 y | 5 years | -50.6% | +34.8% | -71.3% | at low |
| alltime | all time | -50.6% | +34.8% | -71.3% | at low |
Achilles Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $86.05 M(-9.5%) |
| June 2024 | - | $95.11 M(-15.3%) |
| Mar 2024 | - | $112.32 M(-14.6%) |
| Dec 2023 | $131.54 M(-24.1%) | $131.54 M(-6.1%) |
| Sept 2023 | - | $140.14 M(-2.5%) |
| June 2023 | - | $143.71 M(-9.3%) |
| Mar 2023 | - | $158.46 M(-8.6%) |
| Dec 2022 | $173.34 M | $173.34 M(-3.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $179.89 M(-10.8%) |
| June 2022 | - | $201.59 M(-14.9%) |
| Mar 2022 | - | $236.93 M(-11.0%) |
| Dec 2021 | $266.32 M(+49.7%) | $266.32 M(-5.5%) |
| Sept 2021 | - | $281.88 M(-5.8%) |
| June 2021 | - | $299.32 M(+87.9%) |
| Mar 2021 | - | $159.26 M(-10.5%) |
| Dec 2020 | $177.85 M(+82.2%) | $177.85 M |
| Dec 2019 | $97.59 M | - |
FAQ
- What is Achilles Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Achilles Therapeutics?
- What is Achilles Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Achilles Therapeutics?
- What is Achilles Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Achilles Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ACHL is $131.54 M
What is the all time high annual cash & cash equivalents for Achilles Therapeutics?
Achilles Therapeutics all-time high annual cash & cash equivalents is $266.32 M
What is Achilles Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ACHL is $86.05 M
What is the all time high quarterly cash and cash equivalents for Achilles Therapeutics?
Achilles Therapeutics all-time high quarterly cash and cash equivalents is $299.32 M
What is Achilles Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ACHL quarterly cash and cash equivalents has changed by -$45.49 M (-34.58%)